+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Alcoholic Hepatitis Treatment Market: Global Opportunity Analysis and Industry Forecast, 2025-2034

  • PDF Icon

    Report

  • 299 Pages
  • May 2025
  • Region: Global
  • Allied Market Research
  • ID: 6119879

Alcoholic Hepatitis Treatment Market

The alcoholic hepatitis treatment market was valued at $668.44 million in 2024 and is estimated to reach $1.06 billion by 2034, exhibiting a CAGR of 4.7% from 2025 to 2034.

Alcoholic hepatitis is a severe and potentially life-threatening inflammatory liver condition caused by excessive alcohol consumption. It is characterized by symptoms such as jaundice, liver enlargement, and liver failure in advanced stages. Treatment typically involves lifestyle modifications, corticosteroids, nutritional therapy, and in some cases, liver transplantation. With increase in global prevalence of alcohol abuse and liver-related disorders, the alcoholic hepatitis treatment market is witnessing gradual growth. The market comprises pharmaceuticals, biologics, and supportive therapies aimed at managing symptoms and halting disease progression.

Rise in incidence of alcohol use disorder (AUD) globally and surge in awareness about liver-related health conditions significantly drive the growth of the alcoholic hepatitis treatment market. In addition, increase in burden of liver cirrhosis and related complications fuels the demand for more effective treatment options. The introduction of new clinical guidelines and government-backed awareness programs boosts early diagnosis and therapeutic intervention. Furthermore, ongoing R&D activities and advancements in drug development, especially involving anti-inflammatory and immune-modulating agents, are expected to accelerate market growth.

However, several restraints hinder the expansion of the alcoholic hepatitis treatment market. These include the limited availability of targeted treatment options and the poor efficacy of existing therapies such as corticosteroids, which are not effective in all patients. In addition, the social stigma associated with alcohol-related diseases, lack of adherence to treatment, and high cost of advanced therapies such as liver transplantation pose significant challenges. Moreover, limited clinical trial data and a slow drug approval process further delay the development of innovative solutions.

On the other hand, increase in investment in liver disease research, particularly in biologics and regenerative therapies, holds promise for more effective and personalized treatments. The development of novel drug delivery systems and biomarkers for early diagnosis could improve therapeutic outcomes. In addition, public-private partnerships and the expansion of healthcare infrastructure in emerging economies are expected to enhance access to care. Collaborations between biotech firms and academic institutions drive innovation, creating new opportunities for market players in the coming years. For instance, in 2023, Teva Pharmaceutical Industries Ltd. launched a generic version of Votrient (pazopanib hydrochloride) tablets, a treatment for renal cell carcinoma and soft tissue sarcoma.

Segment Review

The alcoholic hepatitis treatment market is segmented into treatment, route of administration, distribution channel, and region. By treatment, the market is segregated into corticosteroids, hemorroheologic agents, and others. By route of administration, the market is categorized into oral and injectable. By distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).

Key Findings

  • By treatment, the corticosteroids segment dominated the market share in 2024.
  • On the basis of route of administration, the oral segment accounted for the largest share in 2024.
  • On the basis of distribution channel, the drug stores and retail pharmacies segment accounted for the largest share in 2024.
  • Region-wise, North America generated the highest revenue in 2024.

Competition Analysis

Major players that operate in the alcoholic hepatitis treatment market are ANI Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Viatris Inc., Advacare Pharma Inc., Aurobindo Pharma, Cumberland Pharmaceuticals Inc., Taj Pharma Group, Apotex Inc., and Sun Pharmaceutical Industries Ltd. Key players have adopted product approval and product launch as key developmental strategies to improve the product portfolio of the alcoholic hepatitis treatment market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • New Product Development/ Product Matrix of Key Players
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Average Selling Price Analysis / Price Point Analysis
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Route of Administration

  • Oral
  • Injectable

By Treatment

  • Corticosteroids
  • Hemorroheologic Agents
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players

  • ANI Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Viatris Inc.
  • Aurobindo Pharma
  • Cumberland Pharmaceuticals Inc.
  • Apotex Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Advacare Pharma Inc.
  • Taj Pharma Group
  • Sun Pharmaceutical Industries Ltd.

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of alcohol-related liver diseases
3.4.1.2. Increase in research funding
3.4.1.3. Growing awareness and early diagnosis
3.4.2. Restraints
3.4.2.1. Limited approved treatment options
3.4.3. Opportunities
3.4.3.1. Expanding clinical trials and research initiatives
CHAPTER 4: ALCOHOLIC HEPATITIS TREATMENT MARKET, BY TREATMENT
4.1. Overview
4.1.1. Market size and forecast
4.2. Corticosteroids
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Hemorroheologic Agents
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: ALCOHOLIC HEPATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Injectable
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: ALCOHOLIC HEPATITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug Stores and Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: ALCOHOLIC HEPATITIS TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Treatment
7.2.3. Market size and forecast, by Route of Administration
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Treatment
7.2.5.1.2. Market size and forecast, by Route of Administration
7.2.5.1.3. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Treatment
7.2.5.2.2. Market size and forecast, by Route of Administration
7.2.5.2.3. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Treatment
7.2.5.3.2. Market size and forecast, by Route of Administration
7.2.5.3.3. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Treatment
7.3.3. Market size and forecast, by Route of Administration
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Treatment
7.3.5.1.2. Market size and forecast, by Route of Administration
7.3.5.1.3. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Treatment
7.3.5.2.2. Market size and forecast, by Route of Administration
7.3.5.2.3. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Treatment
7.3.5.3.2. Market size and forecast, by Route of Administration
7.3.5.3.3. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Treatment
7.3.5.4.2. Market size and forecast, by Route of Administration
7.3.5.4.3. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Treatment
7.3.5.5.2. Market size and forecast, by Route of Administration
7.3.5.5.3. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Treatment
7.3.5.6.2. Market size and forecast, by Route of Administration
7.3.5.6.3. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Treatment
7.4.3. Market size and forecast, by Route of Administration
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Treatment
7.4.5.1.2. Market size and forecast, by Route of Administration
7.4.5.1.3. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Treatment
7.4.5.2.2. Market size and forecast, by Route of Administration
7.4.5.2.3. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Treatment
7.4.5.3.2. Market size and forecast, by Route of Administration
7.4.5.3.3. Market size and forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Treatment
7.4.5.4.2. Market size and forecast, by Route of Administration
7.4.5.4.3. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Treatment
7.4.5.5.2. Market size and forecast, by Route of Administration
7.4.5.5.3. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Treatment
7.4.5.6.2. Market size and forecast, by Route of Administration
7.4.5.6.3. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Treatment
7.5.3. Market size and forecast, by Route of Administration
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Treatment
7.5.5.1.2. Market size and forecast, by Route of Administration
7.5.5.1.3. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Treatment
7.5.5.2.2. Market size and forecast, by Route of Administration
7.5.5.2.3. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Treatment
7.5.5.3.2. Market size and forecast, by Route of Administration
7.5.5.3.3. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Treatment
7.5.5.4.2. Market size and forecast, by Route of Administration
7.5.5.4.3. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2024
CHAPTER 9: COMPANY PROFILES
9.1. Teva Pharmaceutical Industries Ltd.
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. ANI Pharmaceuticals, Inc.
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Cumberland Pharmaceuticals Inc.
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Taj Pharma Group
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.5. Pfizer Inc.
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Viatris Inc.
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Advacare Pharma Inc.
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.8. Aurobindo Pharma
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Apotex Inc.
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.10. Sun Pharmaceutical Industries Ltd.
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
LIST OF TABLES
Table 01. Global Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 02. Alcoholic Hepatitis Treatment Market for Corticosteroids, by Region, 2024-2034 ($Million)
Table 03. Alcoholic Hepatitis Treatment Market for Hemorroheologic Agents, by Region, 2024-2034 ($Million)
Table 04. Alcoholic Hepatitis Treatment Market for Others, by Region, 2024-2034 ($Million)
Table 05. Global Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 06. Alcoholic Hepatitis Treatment Market for Oral, by Region, 2024-2034 ($Million)
Table 07. Alcoholic Hepatitis Treatment Market for Injectable, by Region, 2024-2034 ($Million)
Table 08. Global Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 09. Alcoholic Hepatitis Treatment Market for Hospital Pharmacies, by Region, 2024-2034 ($Million)
Table 10. Alcoholic Hepatitis Treatment Market for Drug Stores and Retail Pharmacies, by Region, 2024-2034 ($Million)
Table 11. Alcoholic Hepatitis Treatment Market for Online Providers, by Region, 2024-2034 ($Million)
Table 12. Alcoholic Hepatitis Treatment Market, by Region, 2024-2034 ($Million)
Table 13. North America Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 14. North America Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 15. North America Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 16. North America Alcoholic Hepatitis Treatment Market, by Country, 2024-2034 ($Million)
Table 17. U.S. Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 18. U.S. Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 19. U.S. Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 20. Canada Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 21. Canada Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 22. Canada Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 23. Mexico Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 24. Mexico Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 25. Mexico Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 26. Europe Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 27. Europe Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 28. Europe Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 29. Europe Alcoholic Hepatitis Treatment Market, by Country, 2024-2034 ($Million)
Table 30. Germany Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 31. Germany Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 32. Germany Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 33. France Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 34. France Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 35. France Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 36. UK Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 37. UK Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 38. UK Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 39. Italy Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 40. Italy Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 41. Italy Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 42. Spain Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 43. Spain Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 44. Spain Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 45. Rest of Europe Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 46. Rest of Europe Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 47. Rest of Europe Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 48. Asia-Pacific Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 49. Asia-Pacific Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 50. Asia-Pacific Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 51. Asia-Pacific Alcoholic Hepatitis Treatment Market, by Country, 2024-2034 ($Million)
Table 52. Japan Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 53. Japan Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 54. Japan Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 55. China Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 56. China Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 57. China Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 58. India Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 59. India Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 60. India Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 61. Australia Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 62. Australia Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 63. Australia Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 64. South Korea Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 65. South Korea Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 66. South Korea Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 67. Rest of Asia-Pacific Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 68. Rest of Asia-Pacific Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 69. Rest of Asia-Pacific Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 70. LAMEA Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 71. LAMEA Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 72. LAMEA Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 73. LAMEA Alcoholic Hepatitis Treatment Market, by Country, 2024-2034 ($Million)
Table 74. Brazil Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 75. Brazil Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 76. Brazil Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 77. Saudi Arabia Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 78. Saudi Arabia Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 79. Saudi Arabia Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 80. South Africa Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 81. South Africa Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 82. South Africa Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 83. Rest of LAMEA Alcoholic Hepatitis Treatment Market, by Treatment, 2024-2034 ($Million)
Table 84. Rest of LAMEA Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024-2034 ($Million)
Table 85. Rest of LAMEA Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024-2034 ($Million)
Table 86. Teva Pharmaceutical Industries Ltd.: Key Executives
Table 87. Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 88. Teva Pharmaceutical Industries Ltd.: Product Segments
Table 89. Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 90. Ani Pharmaceuticals, Inc.: Key Executives
Table 91. Ani Pharmaceuticals, Inc.: Company Snapshot
Table 92. Ani Pharmaceuticals, Inc.: Product Segments
Table 93. Ani Pharmaceuticals, Inc.: Product Portfolio
Table 94. Ani Pharmaceuticals, Inc.: Key Stratergies
Table 95. Cumberland Pharmaceuticals Inc.: Key Executives
Table 96. Cumberland Pharmaceuticals Inc.: Company Snapshot
Table 97. Cumberland Pharmaceuticals Inc.: Product Segments
Table 98. Cumberland Pharmaceuticals Inc.: Product Portfolio
Table 99. Cumberland Pharmaceuticals Inc.: Key Stratergies
Table 100. Taj Pharma Group: Key Executives
Table 101. Taj Pharma Group: Company Snapshot
Table 102. Taj Pharma Group: Product Segments
Table 103. Taj Pharma Group: Product Portfolio
Table 104. Pfizer Inc.: Key Executives
Table 105. Pfizer Inc.: Company Snapshot
Table 106. Pfizer Inc.: Product Segments
Table 107. Pfizer Inc.: Product Portfolio
Table 108. Viatris Inc.: Key Executives
Table 109. Viatris Inc.: Company Snapshot
Table 110. Viatris Inc.: Product Segments
Table 111. Viatris Inc.: Product Portfolio
Table 112. Advacare Pharma Inc.: Key Executives
Table 113. Advacare Pharma Inc.: Company Snapshot
Table 114. Advacare Pharma Inc.: Product Segments
Table 115. Advacare Pharma Inc.: Product Portfolio
Table 116. Aurobindo Pharma: Key Executives
Table 117. Aurobindo Pharma: Company Snapshot
Table 118. Aurobindo Pharma: Product Segments
Table 119. Aurobindo Pharma: Product Portfolio
Table 120. Apotex Inc.: Key Executives
Table 121. Apotex Inc.: Company Snapshot
Table 122. Apotex Inc.: Product Segments
Table 123. Apotex Inc.: Product Portfolio
Table 124. Sun Pharmaceutical Industries Ltd.: Key Executives
Table 125. Sun Pharmaceutical Industries Ltd.: Company Snapshot
Table 126. Sun Pharmaceutical Industries Ltd.: Product Segments
Table 127. Sun Pharmaceutical Industries Ltd.: Product Portfolio
LIST OF FIGURES
Figure 01. Alcoholic Hepatitis Treatment Market, 2024-2034
Figure 02. Segmentation of Alcoholic Hepatitis Treatment Market,2024-2034
Figure 03. Top Impacting Factors in Alcoholic Hepatitis Treatment Market (2024 to 2034)
Figure 04. Top Investment Pockets in Alcoholic Hepatitis Treatment Market (2025-2034)
Figure 05. Moderate Bargaining Power of Suppliers
Figure 06. Moderate Threat of New Entrants
Figure 07. Moderate Threat of Substitutes
Figure 08. Moderate Intensity of Rivalry
Figure 09. Moderate Bargaining Power of Buyers
Figure 10. Global Alcoholic Hepatitis Treatment Market:Drivers, Restraints and Opportunities
Figure 11. Alcoholic Hepatitis Treatment Market, by Treatment, 2024 and 2034(%)
Figure 12. Comparative Share Analysis of Alcoholic Hepatitis Treatment Market for Corticosteroids, by Country 2024 and 2034(%)
Figure 13. Comparative Share Analysis of Alcoholic Hepatitis Treatment Market for Hemorroheologic Agents, by Country 2024 and 2034(%)
Figure 14. Comparative Share Analysis of Alcoholic Hepatitis Treatment Market for Others, by Country 2024 and 2034(%)
Figure 15. Alcoholic Hepatitis Treatment Market, by Route of Administration, 2024 and 2034(%)
Figure 16. Comparative Share Analysis of Alcoholic Hepatitis Treatment Market for Oral, by Country 2024 and 2034(%)
Figure 17. Comparative Share Analysis of Alcoholic Hepatitis Treatment Market for Injectable, by Country 2024 and 2034(%)
Figure 18. Alcoholic Hepatitis Treatment Market, by Distribution Channel, 2024 and 2034(%)
Figure 19. Comparative Share Analysis of Alcoholic Hepatitis Treatment Market for Hospital Pharmacies, by Country 2024 and 2034(%)
Figure 20. Comparative Share Analysis of Alcoholic Hepatitis Treatment Market for Drug Stores and Retail Pharmacies, by Country 2024 and 2034(%)
Figure 21. Comparative Share Analysis of Alcoholic Hepatitis Treatment Market for Online Providers, by Country 2024 and 2034(%)
Figure 22. Alcoholic Hepatitis Treatment Market by Region, 2024 and 2034(%)
Figure 23. U.S. Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 24. Canada Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 25. Mexico Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 26. Germany Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 27. France Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 28. UK Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 29. Italy Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 30. Spain Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 31. Rest of Europe Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 32. Japan Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 33. China Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 34. India Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 35. Australia Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 36. South Korea Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 37. Rest of Asia-Pacific Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 38. Brazil Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 39. Saudi Arabia Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 40. South Africa Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 41. Rest of LAMEA Alcoholic Hepatitis Treatment Market, 2024-2034 ($Million)
Figure 42. Top Winning Strategies, by Year (2024-2024)
Figure 43. Top Winning Strategies, by Development (2024-2024)
Figure 44. Top Winning Strategies, by Company (2024-2024)
Figure 45. Product Mapping of Top 10 Players
Figure 46. Competitive Dashboard
Figure 47. Competitive Heatmap: Alcoholic Hepatitis Treatment Market
Figure 48. Top Player Positioning, 2024
Figure 49. Teva Pharmaceutical Industries Ltd.: Net Revenue, 2022-2024 ($Million)
Figure 50. Teva Pharmaceutical Industries Ltd.: Revenue Share by Segment, 2024 (%)
Figure 51. Ani Pharmaceuticals, Inc.: Net Revenue, 2022-2024 ($Million)
Figure 52. Ani Pharmaceuticals, Inc.: Revenue Share by Segment, 2024 (%)
Figure 53. Ani Pharmaceuticals, Inc.: Revenue Share by Region, 2024 (%)
Figure 54. Cumberland Pharmaceuticals Inc.: Net Revenue, 2022-2024 ($Million)
Figure 55. Pfizer Inc.: Net Revenue, 2022-2024 ($Million)
Figure 56. Pfizer Inc.: Revenue Share by Segment, 2024 (%)
Figure 57. Pfizer Inc.: Revenue Share by Region, 2024 (%)
Figure 58. Viatris Inc.: Net Sales, 2022-2024 ($Million)
Figure 59. Viatris Inc.: Revenue Share by Segment, 2024 (%)
Figure 60. Aurobindo Pharma: Net Revenue, 2022-2024 ($Million)
Figure 61. Aurobindo Pharma: Revenue Share by Region, 2024 (%)
Figure 62. Sun Pharmaceutical Industries Ltd.: Net Revenue, 2022-2024 ($Million)
Figure 63. Sun Pharmaceutical Industries Ltd.: Revenue Share by Region, 2024 (%)

Companies Mentioned

  • ANI Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Viatris Inc.
  • Aurobindo Pharma
  • Cumberland Pharmaceuticals Inc.
  • Apotex Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Advacare Pharma Inc.
  • Taj Pharma Group
  • Sun Pharmaceutical Industries Ltd.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...